| DM (n = 149) | Non-DM (n = 188) | p value |
---|---|---|---|
At the time of PCI | |||
 Aspirin, n (%) | 139 (93) | 173 (92) | 0.41 |
 Clopidogrel, n (%) | 73 (49) | 112 (60) | 0.061 |
 Prasugrel, n (%) | 52 (35) | 53 (28) | 0.20 |
 Ticlopidine, n (%) | 7 (5) | 8 (4) | 1.0 |
  Statin, n (%) | 80 (54) | 92 (49) | 0.22 |
 Insulin, n (%) | 24 (16) | 0 (0) | N/A |
 Biguanide, n (%) | 38 (26) | 0 (0) | N/A |
 DPP-4 inhibitor, n (%) | 59 (40) | 0 (0) | N/A |
 SGLT-2 inhibitor, n (%) | 4 (3) | 0 (0) | N/A |
 Thiazolidine, n (%) | 18 (12) | 0 (0) | N/A |
 Sulfonylurea, n (%) | 39 (26) | 0 (0) | N/A |
 Glinide, n (%) | 6 (4) | 0 (0) | N/A |
 α-glucosidase inhibitor, n (%) | 26 (17) | 0 (0) | N/A |
At the time of CAS evaluation | |||
 Aspirin, n (%) | 149 (100) | 186 (99) | 0.31 |
 Clopidogrel, n (%) | 79 (53) | 104 (55) | 0.74 |
 Prasugrel, n (%) | 63 (42) | 64 (34) | 0.14 |
 Ticlopidine, n (%) | 6 (4) | 8 (4) | 1.0 |
 Statin, n (%) | 102 (69) | 142 (76) | 0.094 |
 Insulin, n (%) | 25 (17) | 0 (0) | N/A |
 Biguanide, n (%) | 43 (29) | 0 (0) | N/A |
 DPP-4 inhibitor, n (%) | 62 (42) | 0 (0) | N/A |
 SGLT-2 inhibitor, n (%) | 5 (3) | 0 (0) | N/A |
 Thiazolidine, n (%) | 18 (12) | 0 (0) | N/A |
 Sulfonylurea, n (%) | 40 (27) | 0 (0) | N/A |
 Glinide, n (%) | 10 (7) | 0 (0) | N/A |
 α-glucosidase inhibitor, n (%) | 31 (21) | 0 (0) | N/A |